Group 1 - Twist Bioscience's revenue growth is moderating due to macro headwinds and temporary factors affecting growth [1] - Narweena, an asset manager, focuses on identifying market dislocations and businesses with long-term growth opportunities [1] - The investment strategy emphasizes smaller cap stocks and markets with less obvious competitive advantages [1] Group 2 - An aging population and low population growth are expected to create new investment opportunities, contrasting with past trends [1] - Many industries may experience stagnation or secular decline, potentially improving business performance due to reduced competition [1] - The economy is increasingly dominated by asset-light businesses, leading to a decline in infrastructure investment needs [1]

Twist Bioscience's ( TWST ) revenue growth continues to moderate, which is at least partly due to macro headwinds. There are also some temporary factors weighing on growth at the moment. This isn't surprising, as I previously suggested that headwindsRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by identifying ...

Twist Bioscience Corporation (NASDAQ:TWST) is one of the best gene-editing stocks to buy according to hedge funds. On November 4, Steven Etoch, an analyst at Stephens, began coverage of Twist Bioscience Corporation (NASDAQ:TWST). Etoch assigned an Overweight rating on the stock and a $41 price target. The analyst cited Twist’s “differentiated, technology-driven DNA synthesis platform” as a key factor in the decision. The platform serves several markets, including drug discovery, next-generation sequencing ...

Twist Bioscience (NasdaqGS:TWST) 2025 Conference November 17, 2025 03:20 PM ET Company ParticipantsAdam Laponis - CFOEmily Leproust - CEODoug Schenkel - Head of Life Science & Diagnostic ToolsDoug SchenkelAll right, good afternoon, everybody. This is Doug Schenkel from Wolfe Research. It's my pleasure to welcome Emily Leproust, Twist's CEO, and Adam Laponis, the company's Chief Financial Officer. Thanks to the two of you for being here. I know it was a quick turnaround with, it feels like it was a while ago ...

Twist Bioscience (NasdaqGS:TWST) 2025 Conference November 17, 2025 03:20 PM ET Company ParticipantsAdam Laponis - CFOEmily Leproust - CEOConference Call ParticipantsDoug Schenkel - AnalystDoug SchenkelAll right, good afternoon, everybody. This is Doug Schenkel from Wolfe Research. It's my pleasure to welcome Emily Leproust, Twist's CEO, and Adam Laponis, the company's Chief Financial Officer. Thanks to the two of you for being here. I know it was a quick turnaround with, it feels like it was a while ago, bu ...

Industry Overview - Genetic manipulation, or gene editing, involves altering the genetic material (DNA) of organisms, which gained traction in the 1970s with the creation of recombinant DNA (rDNA) molecules and saw significant commercialization growth with the introduction of the CRISPR-Cas9 system in the 2010s [2][3] - The CRISPR ecosystem currently has 1,031 active companies, with 298 raising approximately $35.8 billion across over 1,200 funding rounds, and the industry is projected to reach a size of $10.8 billion by the end of 2025, expanding at a 16.9% CAGR to nearly $24 billion by 2030 [3] Investment Insights - Hedge funds are showing high interest in gene editing stocks, with notable investments such as BlackRock acquiring over 980,000 additional shares in a leading gene editing company in Q3 2025 [5] - The methodology for identifying the best gene-editing stocks involved reviewing sector exposure through ETF holdings and media coverage, focusing on companies developing and commercializing gene-editing technologies, resulting in a list of nine firms with strong hedge fund support [7] Company Highlights Editas Medicine Inc. (NASDAQ:EDIT) - Editas Medicine is recognized as a top gene-editing stock, with 11 hedge fund holders, and has a price target raised to $4.60 from $4.00 by Clear Street, which noted the company's extended cash runway into Q3 2027 [9][10] - The company reported Q3 2025 results with an EPS of –$0.28 and revenues increasing to $7.5 million from $0.1 million in Q3 2024, driven by collaboration with Bristol Myers Squibb [11] - Editas is focused on developing transformative in vivo therapies using CRISPR technology, with plans to file for IND/CTA by mid-2026 and achieve human proof-of-concept data by year-end 2026 [12] Twist Bioscience Corporation (NASDAQ:TWST) - Twist Bioscience has 23 hedge fund holders and received an Overweight rating with a $41 price target from analyst Steven Etoch, who highlighted its differentiated DNA synthesis platform [13][14] - The company has experienced strong revenue growth of 22.7% over the past year and a five-year CAGR of 42%, with expectations to reach adjusted EBITDA break-even by the end of fiscal year 2026 [14] - Twist's proprietary silicon-based platform enables rapid gene synthesis for applications in drug discovery, diagnostics, and precision medicine, strengthening its market position [16]

Core Insights - Artisan Partners' "Artisan Small Cap Fund" reported strong performance in Q3 2025, with major US indices reaching record highs and the fund's Investor Class returning 8.69% [1] - Twist Bioscience Corporation (NASDAQ:TWST) was highlighted as a detractor in the fund's performance, with a one-month return of -20.34% and a 52-week loss of 37.05% [2][3] Fund Performance - The Artisan Small Cap Fund's Advisor Class fund returned 8.75%, and the Institutional Class fund returned 8.73%, while the Russell 2000 Growth Index returned 12.19% [1] - The fund's top 5 holdings were mentioned as key picks for 2025 [1] Company Analysis: Twist Bioscience Corporation - Twist Bioscience reported 18% revenue growth, driven by demand in next-generation sequencing, despite weaker sales in synthetic biology products [3] - The company has a market capitalization of $1.58 billion, with shares closing at $26.87 on November 14, 2025 [2] - The partnership with Veracyte is viewed as a validation of Twist's platform, potentially driving long-term upside [3] Hedge Fund Interest - Twist Bioscience was held by 23 hedge fund portfolios at the end of Q2 2025, a decrease from 30 in the previous quarter [4] - The company reported revenue of $99 million in Q4 2025, reflecting a 17% year-over-year growth [4]

Core Insights - Twist Bioscience (TWST) stock has experienced a significant decline of 10.1% in one day, raising concerns about potential deeper issues beyond temporary weakness [2] - The company is valued at $1.6 billion with a revenue of $362 million, and its stock is currently trading at $26.87 [2] - Revenue growth over the past year is reported at 22.7%, but the operating margin stands at -39.3% [2] - The stock is trading at a P/E multiple of -18.9 and a P/EBIT multiple of -9.5, indicating moderate operational performance and valuation, leading to it being considered fairly priced [3] Financial Position - The company has a debt-to-equity ratio of 0.05 and a cash-to-assets ratio of 0.39, suggesting a strong liquidity position [2] - TWST stock has historically underperformed compared to the S&P 500 during economic downturns, with a notable decline of 94.5% from its peak of $207.97 on January 20, 2021, to $11.49 on May 2, 2023 [7] - The stock has not yet returned to its pre-crisis high, with the highest price since then being $58.88 on July 23, 2024 [7] Market Performance - The stock dropped 43.9% from a high of $35.15 on March 6, 2020, to $19.71 on March 18, 2020, compared to a 33.9% decline for the S&P 500 [7] - In December 2018, TWST stock declined by 47.6% from a peak of $31.08 to $16.30, while the S&P 500 experienced a peak-to-trough decline of 19.8% [8] - Despite these declines, the stock has shown the ability to fully rebound to its pre-crisis peaks in previous instances [8]

Financial Performance - The company incurred net losses of $204.6 million, $208.7 million, and $77.7 million for the years ended September 30, 2023, 2024, and 2025, respectively, with an accumulated deficit of $1,319.6 million as of September 30, 2025[117]. - The company has incurred limited revenue from product sales to date and expects increasing costs as it grows, which may hinder its ability to achieve profitability[117]. - The company anticipates net losses and negative operating cash flows for the near future, indicating a potential need for additional financing[186]. - Future capital requirements will depend on the development of new products and manufacturing processes, as well as the costs associated with these initiatives[187]. - Increased operating costs have been experienced, attributed to inflation, but the company does not believe inflation has materially affected its financial condition[160]. Revenue Generation - The company relies heavily on its synthetic DNA products, which have generated substantially all of its revenue to date, and aims to strengthen its synthetic biology and NGS product groups while diversifying into other sectors[126]. - The company must attract new customers and retain existing ones to grow its business, particularly in the synthetic DNA and NGS tool markets, where it currently generates significant revenue from liquid biopsy applications[131]. - 42% of the company's revenue for the fiscal year ended September 30, 2025, was generated from international customers, up from 40% in both 2024 and 2023[195]. - Customer spending on research and development is subject to significant variation, impacting demand for the company's products[144]. - The company does not have long-term contracts with customers, making revenue predictions challenging and exposing it to potential order reductions[147]. Competition and Market Risks - The company faces significant competition from established players in the synthetic biology and life sciences tools industries, which may lead to pricing pressures and impact its market share[130]. - Pricing pressures may arise, and if the company cannot pass on cost increases to customers, it could adversely affect its financial position and results[169]. - The company faces significant risks from geopolitical tensions, including new U.S. tariffs that could increase production costs and disrupt supply chains[143]. - Changes in currency exchange rates may negatively impact revenue from international customers, making products more expensive and affecting competitiveness[196]. - The company faces operational and financial risks when expanding into international markets, including longer payment cycles and difficulties in collecting accounts receivable[195]. Supply Chain and Operational Risks - The company is dependent on a single-source supplier for a critical component in its DNA synthesis process, and any disruption could adversely affect its operations[113]. - The company relies on a single-source supplier for a critical component in its DNA synthesis process, which could lead to operational delays if supply is interrupted[148]. - There is a need for the single-source supplier to increase manufacturing capacity to meet anticipated market demand, which may require significant investment and could face challenges[153]. - Existing suppliers may not meet increasing demand as the company grows, necessitating the search for additional suppliers, which could lead to delays and added costs[155]. - The company has stable relationships with suppliers, but any deterioration could lead to production capacity shortages and inability to fulfill customer demand[157]. Intellectual Property and Compliance - The company’s ability to protect its intellectual property is uncertain, and failure to do so could allow competitors to replicate its products[113]. - The company may not be able to protect its intellectual property rights effectively in all jurisdictions, which could adversely affect its competitive position[216]. - The company faces challenges in enforcing its patents and intellectual property rights in countries like China and India, which may lead to significant costs and risks of invalidation[217]. - The company may incur substantial costs and management distraction from litigation related to patent enforcement and intellectual property rights[222]. - The company is subject to data privacy and protection laws, which could lead to significant consequences such as business interruption and regulatory fines if noncompliance occurs[175]. Management and Governance - The company is highly dependent on its senior management and key personnel, with potential risks associated with losing these individuals[161]. - Strategic transactions, including acquisitions, may disrupt the business and could lead to dilution of stockholder value[165]. - The company has experienced at least one ownership change in the past, which may limit the use of net operating loss carryforwards to offset future taxable income[197]. - Compliance with public company regulations has increased legal and financial costs, requiring significant management attention[205]. - The company is required to advance expenses to directors and officers in connection with defending proceedings, with certain limitations on indemnification[267]. Technology and Innovation - The integration of AI and machine learning into operations presents both opportunities and risks, including compliance and reputational challenges[142]. - The company must continually innovate to remain competitive in the rapidly changing synthetic biology industry[139]. - The company introduced IVDR-compliant Precision Dx products for whole exome sequencing in February 2024 to meet EU regulatory requirements[179]. - The company may need to obtain CLIA certification in the future, which could divert management's attention and disrupt core operations[180]. - The complexity of licensing agreements may lead to disputes over royalty obligations, which could impact the company's ability to market its products[239]. Financial Position and Stock Market - The company has never declared or paid dividends on its common stock and does not intend to do so in the foreseeable future, relying on stock price appreciation for investor gains[241]. - The market price of the company's common stock is likely to be volatile, influenced by various factors including economic conditions and competition[250]. - The company has experienced fluctuations in its quarterly and annual operating results, which may continue to affect stock value[254]. - Future sales and issuances of common stock could result in dilution of existing stockholders' ownership and potentially lower stock prices[265]. - The company’s operating results may differ significantly from its guidance, which is based on management's estimates and assumptions[259]. ESG and Regulatory Compliance - Increasing scrutiny around ESG practices may impose additional costs and expose the company to reputational risks, affecting investment strategies[268]. - Regulatory authorities are imposing mandatory disclosure requirements related to ESG matters, which could adversely impact the company's business if not adequately addressed[269]. - Enhancements to processes and controls for evolving ESG reporting standards may incur significant costs and require additional resources[269]. - Companies perceived as not responding appropriately to evolving ESG expectations may suffer reputational damage, impacting financial condition and stock price[268].

方舟将资金通过三只不同的ETF，增持了加密基础设施公司Bitmine Immersion Technologies (BMNR) 的 股份。与此同时，买入了价值约551万美元的Twist Bioscience (TWST) 股票，以及价值约300万美元的 Beam Therapeutics (BEAM) 股票。 由凯西·伍德（Cathie Wood）领导的方舟投资公司对其旗下ETF的持仓进行了显著调整。方舟大幅卖出 了社交媒体平台Pinterest (PINS) 的股票，总价值约5020万美元，延续了近期的减持趋势。此举可能与 Pinterest最近公布的季度业绩未达预期以及对未来指引疲软有关，特别是其首席财务官提及北美广告支 出放缓的情况。 （文章来源：证券时报网） ...